9/12/2013 8:06:07 AM
Cheshire's Alexion Pharmaceuticals Inc. presented preliminary data Tuesday in Austria that it says is an encouraging sign its blockbuster drug Soliris may be a viable treatment to prevent kidney transplant rejections. The Phase 2 study seeks to evaluate Soliris as an investigational therapy to prevent acute antibody-mediated rejection, or AMR, in sensitized deceased-donor kidney transplant patients. Soliris, which is approved in a number of countries for treatment of several blood disorders, is not yet approved to prevent organ transplant rejections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by